Global pharmaceutical company, Pfizer has placed 2.75% notes in a public offering. Due 2026, the notes will raise gross proceeds of $1.25bn, which will be used for general corporate purposes by the company. The offering will be completed on 3 June 2016.
In a separate offering, Pfizer has placed 1.2% notes, due 2018 to raise $1.25bn. It has also priced public offering of 1.45% notes due 2019 to raise $0.85bn, 1.95% notes due 2021 for raising gross proceeds of $1.15bn, and 4.4% notes due 2044 to raise $500m.
Pursuant to the terms of the agreement, ArcherDX will conduct a series of diagnostic tests using its anchored multiplex PCR (AMP) chemistry that will be run on the Illumina MiSeqDx instrument.
The partnership allows the companies to develop a companion test aligned to the current and next generations of targeted therapies instead of a single companion diagnostic for a single therapy. The combined test will improve patient outcomes and reduce the sample and cost burdens of clinical sequencing in the future, says ArcherDX’s CEO.
Mylan N.V has announced the offering of 3.95% senior notes in a private placement. Due 2026, the notes will be issued at 99.231% of the principal amount and will raise gross proceeds of $2.25bn.
Qualified institutional buyers in and outside the US and non-US persons in reliance on Regulation S under the Securities Act will subscribe to the placement, which will be closed on or before 9 June 2016.
Proceeds from the offering will be used by the company to fund the acquisition of Meda AB, to repay debts of its subsidiaries, and other costs.
In a separate placement, Mylan has announced 2.5% senior notes, due 2019, to raise $1bn, 3.15% senior notes, due 2021, to raise $2.25bn, and 5.25% senior notes, due 2046, to raise $1bn.
As per the agreement, DBV will develop and commercialise an innovative, ready-to-use, standardised atopy patch-test tool using its proprietary Viaskin technology platform for the diagnosis of Cow’s Milk Protein Allergy (CMPA) in infants.
Nestle has obtained exclusive worldwide rights to market DBV’s diagnostic tool. The health science company will pay €10m ($11.12m) as an upfront payment to DBV, which will be responsible for the development stages, including industrialisation and regulatory submissions of the tool.
DBV is also eligible to receive development milestones and other royalty payments on sales, under the terms of the agreement.
The acquisition, which is planned for completion in August 2016, will allow Atos Medical to continue developing its flagship ENT devices for laryngectomy prostheses and accessories for tracheostomy and tympanostomy care.
Image: Patch tests. Photo: courtesy of DBV Technologies.